A new method can improve treatment for patients with chronic myeloid leukaemia by predicting which medication will be most effective. The method also works for other forms of cancer where resistance ...

ESK-001, out of the 3 molecules, has the fullest target inhibition of TYK2 as measured by IC50 and IC90. This gives ESK-001 the ability to potentially increase efficacy with comparable dosing.

SELLAS has announced positive data from preclinical studies identifying the ASXL1 mutation as a predictor of response to ...

All cell lines were analyzed for presence of ASXL1 mutations and other genetic markers. High efficacy was prespecified as IC50 100 nM, significantly lower than the standard threshold definition for an ...